ATM and neoplasm: Poly(ADP-ribose) polymerase (PARP) inhibitors have garnered significant attention due to their ability to induce synthetic lethality in tumor cells with homologous recombination repair (HRR) dysfunction, such as mutations in BRCA1, BRCA2, or other HRR-related genes like ataxia telangiectasia-mutated (ATM) [8, 9].